Skip to main content

Table 4 Characteristics of CAR-T cell patients according to the outcome at 1 year

From: The use of ICU resources in CAR-T cell recipients: a hospital-wide study

N (%) or Median (IQR] 1-year survivors (n = 45) 1-year decedents (n = 26) p
Demographics
 Age 60 [32–68] 58 [41–65] 0∙84
 Male gender 24 (53%) 18 (69%) 0∙29
Comorbidities
 Hypertension 4 (9%) 6 (23%) 0.19
 Diabetes 3 (7%) 1 (4%) 1
 Chronic kidney disease 2 (4.5%) 0 0.73
Body mass index (kg/m2) 24.5 [22–27] 23.5 [22–25.5] 0.40
Performance status 1 [1–2] 2 [1–2] 0.023
Hematological malignancy    0.73
 Diffuse large B cell lymphoma 33 (73%) 20 (77%)  
 Lymphoblastic leukemia 11 (24.5%) 6 (23%)  
 Multiple myeloma 1 (2%) 0  
 Median number of previous treatment lines 3 [2–4] 4 [3–5] 0.12
Time between CAR-T cell infusion and ICU admission (days) 6 [4–8] 5 [3–7] 0.21
Reason for ICU admission    0.04
 CRS 22 (49%) 11 (42%)  
 CRS or sepsis 10 (22%) 3 (11.5%)  
 Sepsis 13 (29%) 8 (31%)  
 Disease progression 0 4 (15.5%)  
Clinical and biological features at ICU admission
 Mean arterial blood pressure (mmHg) 66 [60–78] 70 [63–82] 0.24
 Temperature ( °C) 39.9 [38.9–40.3] 38.9 [38–39.7] 0.003
 Neutropenia 25 (55.5%) 22 (85%) 0.02
SOFA score 4 [2–6] 5 [2–7] 0.21
Non-specific treatments in the ICU at day 1
 Fluid resuscitation at day 1 (mL) 1000 [0–2000] 500 [0–1500] 0.23
 Vasopressors 10 (22%) 8 (31%) 0.61
 Mechanical ventilation 2 (4.5%) 0 0.73
 Renal replacement therapy 0 1 (4%) 0.78
  1. CRS cytokine release syndrome, ICU intensive care unit, SOFA sepsis-related organ Failure Assessment